MOL #41236 1 Cellular and in vivo activity of JNJ-28871063: a non-quinazoline pan-ErbB kinase inhibitor that crosses the blood brain barrier and displays efficacy against intracranial tumors. Stuart L. Emanuel, Terry V. Hughes 1 , Mary Adams 2 , Catherine A. Rugg 3 , Angel Fuentes-Pesquera 3 , Peter J. Connolly 4 , Niranjan Pandey 5 , Sandra Moreno-Mazza 3 , Jeannene Butler 6 , Virna Borowski 7 , Steven A. Middleton 8 , Robert H. Gruninger, Jennifer R. Story, Cheryl Napier, Beth Hollister and Lee M. Greenberger 9 . Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey (S.L.E., T.V.H., M.A., C.A.R., A.F.P., P.J.C., N.P., S.M.M., J.B., V.B., S.A.M., R.H.G., L.G.) and Piedmont Research Center, Morrisville, North Carolina (J.R.S., C.N., B.H). Molecular Pharmacology Fast Forward. Published on November 1, 2007 as doi:10.1124/mol.107.041236 Copyright 2007 by the American Society for Pharmacology and Experimental Therapeutics. This article has not been copyedited and formatted. The final version may differ from this version. Molecular Pharmacology Fast Forward. Published on November 1, 2007 as DOI: 10.1124/mol.107.041236 at ASPET Journals on December 20, 2021 molpharm.aspetjournals.org Downloaded from